PCSK9 and cancer: These siRNA therapeutics primarily address cardiovascular diseases, cancers, neurological disorders, and immune system-related diseases, targeting key molecules including: transthyretin (TTR), aminolevulinic acid synthase1 (ALAS1), hydroxysteroid (17-beta) dehydrogenase1 (HAO1), proprotein convertase subtilisin/kexin type 9 (PCSK9), and lactate dehydrogenase (LDH).